JAK2 and essential thrombocythemia: MPNs are associated with somatic mutations including Janus kinase 2 (JAK2)v617F [10–12] present in almost all PV and approximately half of ET and PMF patients [13], and Calreticulin (CALR) mutation, present in 20–35% of ET and PMF patients [14].